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Mina Bakhit, Natalia Krzyzaniak, Joanne Hilder, Justin Clark, Anna Mae Scott and Chris Del Mar
Use of methenamine hippurate to prevent urinary 
tract infections in community adult women:
a systematic review and meta-analysis
INTRODUCTION
Use of antibiotics gives rise to antibiotic 
resistance, a health crisis that is becoming 
increasingly critical to address. By 2050, 
10 million lives per year and a cumulative 
100 trillion USD of economic output will be 
at risk due to the rise of antibiotic-resistant 
infections, unless proactive solutions can be 
found now to slow down the rise of antibiotic 
resistance.1 Conditions often treated with 
antibiotics and a major source of antibiotic 
overuse are urinary tract infections (UTIs). 
UTIs are very common among women, with 
50%–60% of women in the US experiencing 
at least one UTI in their lifetime.2
A common dilemma for primary care 
clinicians is the management of women who 
have experienced UTIs and re-present with 
symptoms suggestive of a recurrent UTI. 
The pain (dysuria), urgency, and frequency 
associated with recurrent UTIs are highly 
unpleasant and can disrupt social and 
occupational activities; all too often, primary 
care clinicians treat these symptoms — 
which are suggestive of UTI — by prescribing 
antibiotics.
If safe, effective treatment alternatives 
were available, it would be possible to 
reduce antibiotic prescribing. One possible 
alternative is methenamine salts, for 
example, methenamine hippurate, which do 
not cause antibiotic resistance and act as a 
bacteriostatic agent through the production 
of formaldehyde from hexamine in the 
urine.3 Methenamine hippurate is generally 
safe, and can be used in pregnancy.4,5 It 
can cause mild gastrointestinal symptoms, 
and must be used with caution in cases of 
dehydration, and liver and renal disease.6 A 
previous review of methenamine hippurate 
compared with no treatment found a 
significant reduction in UTI symptoms in 
people without renal tract abnormalities.7 
However, a comparative effectiveness has 
not been explored.
The aim of this systematic review was 
to focus on randomised controlled trials 
(RCTs) of adult women in the community 
with a history of recurrent UTIs, who used 




The review protocol was developed 
prospectively and registered at the Center 
for Open Science.8 The authors followed the 
2-week systematic review processes9 and 
the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses statement.10
Inclusion and exclusion criteria
Included studies comprised adult women 
(aged ≥18 years) with a history of recurrent or 
confirmed UTIs, as defined by study authors, 
from the community. Studies involving 
women with spinal cord injuries or those 
with catheters (long-term or short-term 
after surgery) were excluded as these groups 
may experience UTI at different rates from 
Abstract
Background
Urinary tract infections (UTIs) are often treated 
with antibiotics and are a source of antibiotic 
overuse.
Aim
To systematically review randomised controlled 
trials (RCTs) of adult women in the community 
with a history of recurrent UTIs and who use 
methenamine hippurate prophylactically.
Design and setting
Systematic review of women in the UK, Australia, 
Norway, and US (aged ≥18 years) with recurrent 
UTIs receiving methenamine hippurate against 
placebo or no treatment, and antibiotics.
Method
The authors searched three databases, clinical 
trial registries, and performed forward–backward 
citation analysis on references of included studies.
Results
Six studies involving 557 participants were included 
(447 were analysed). Of the six studies, five were 
published and one was an unpublished trial 
record with results, three compared methenamine 
hippurate against placebo or control, and 
three compared methenamine hippurate with 
antibiotics. For the number of patients who 
remained asymptomatic, methenamine hippurate 
showed a non-statistically significant trend of 
benefit versus antibiotics over 12 months (risk 
ratio [RR] 0.65, 95% confidence interval [CI] = 0.40 
to 1.07, I 2 49%), versus control over 6 or 12 months 
(RR 0.56, 95% CI = 0.13 to 2.35, I 2 93%), and a non-
statistically significant trend versus any antibiotic 
for abacteruria (RR 0.80, 95% CI = 0.62 to 1.03, 
I 2 23%). A similar non-statistically significant 
trend of benefits for methenamine hippurate for 
the number of UTI or bacteriuric episodes was 
found, and a non-statistically significant difference 
in the number of patients experiencing adverse 
events between methenamine hippurate and any 
comparator, with a trend towards benefit for the 
methenamine hippurate, was identified. Antibiotic 
use and resistance were not consistently reported.
Conclusion
There is insufficient evidence to be certain of the 
benefits of methenamine hippurate to prevent 
UTI. Further research is needed to test the 
drug's effectiveness in preventing UTIs and as an 
alternative for antibiotic treatment for UTI.
Keywords
antibiotics; methenamine hippurate; primary care; 
systematic review; urinary tract infections.
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the general population. Studies of males and 
mixed-gender studies for which separate 
results for women were not available were 
excluded.
Studies of methenamine hippurate 
compared with placebo/no treatment or 
compared with any antibiotic were included; 
studies that reported the use of an acidifying 
agent for the urine (for example, ascorbic 
acid or sodium dihydrogen phosphate) 
combined with methenamine hippurate 
were excluded if this was not given to both 
the control and intervention arms. The 
primary outcome was UTI manifested by 
any combination of the following symptoms: 
dysuria, nocturia, urgency, fever, burning, 
pyuria, frequency, suprapubic pain, and 
loin pain. The secondary outcomes were: 
adverse events, bacteriuria, antibiotic use, 
and antibiotic resistance. 
RCTs of any design (for example, parallel, 
cluster, or crossover) were included. The 
authors excluded observational studies and 
reviews of primary studies (for example, 
systematic reviews and literature reviews).
Information sources and search strategy
PubMed, EMBASE, and the Cochrane 
Central Register of Controlled Trials 
(CENTRAL) were searched from inception 
until 13 July 2020. The search string was 
designed in PubMed, then translated for use 
in the other databases using the Polyglot 
Search Translator.11 The complete search 
strings for all databases are provided in 
Supplementary Box S1. 
Clinical trial registries were searched on 
13 July 2020 via CENTRAL, which includes 
the World Health Organization’s International 
Clinical Trials Registry Platform and 
clinicaltrials.gov. On 15 July 2020, a citation 
analysis on the included studies identified by 
the database searches was conducted; this 
comprised a backward (cited) analysis, which 
was conducted manually as the articles 
were not indexed in Scopus, and a forward 
(citing) analysis, which was completed using 
Scopus. The citation analysis was screened 
against the inclusion criteria. 
No restrictions by language or publication 
date were imposed. Google’s translation 
services were used to translate the full text of 
trials that had not been published in English. 
Included publications were those that were 
published in full. Publications available 
as abstract only (for example, conference 
abstracts) were included if they had a clinical 
trial registry record, or other public report, 
with the additional information required for 
inclusion; publications available as abstract 
only (for example, conference abstracts) with 
no additional information available were 
excluded.
Screening and data extraction
Three review authors independently screened 
the titles and abstracts for inclusion against 
the inclusion criteria. One author retrieved 
the full texts, and the three authors who 
screened titles and abstracts screened the 
full texts for inclusion. Any disagreements 
were resolved by discussion, or reference to 
a fourth author.
A data-extraction form was used for study 
characteristics and outcome data, which was 
piloted on two studies in the review. Three 
authors extracted data from the included 
studies; Box 1 outlines the information that 
was extracted.
Risk of bias
Three review authors independently assessed 
the risk of bias for each included study using 
the Cochrane Risk of Bias Tool (version 1), 
as outlined in the Cochrane Handbook for 
Systematic Reviews of Interventions.12 All 
disagreements were resolved by discussion 
or by referring to a fourth author. 
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How this fits in 
Urinary tract infections (UTIs) are often 
treated with antibiotics and are a major 
source of antibiotic overuse. In the interests 
of decreasing antibiotic prescribing, one 
alternative treatment is methenamine 
hippurate, which has reported benefits 
and a mild side-effect profile; however, its 
comparative effectiveness has not been 
widely explored. This study focused on 
the efficacy of methenamine hippurate 
compared with both control/no treatment 
and any antibiotic. Overall, the insufficiency of 
evidence precludes a firm recommendation 
on the use of methenamine hippurate 
prophylactically; however, there is enough 
evidence to warrant further research to 
investigate its benefits.
Box 1. List of extracted information
• Methods: study authors, location, study design, and duration of follow-up
• Participants: n, age (mean/median, range/SD), number of documented previous UTIs, recent antibiotic 
use, and whether currently pregnant 
• Interventions: methenamine hippurate 
• Comparators: placebo/no treatment or any antibiotic 
• Primary and secondary outcomes: UTI symptoms, adverse events (such as nausea, diarrhoea, rash, or 
any symptoms reported as an adverse event by the trial author), bacteriuria, antibiotic use, and antibiotic 
resistance 
SD = standard deviation. UTI = urinary tract infection.
Data synthesis
Review Manager 5 (version 5.4) was used to 
calculate the treatment effect. Rate ratios 
were used for results reporting the number 
of events only, and risk ratios (RRs) or odds 
ratios (ORs) were used for results reporting 
the number of patients with an event. The 
authors planned to use mean differences 
or standardised mean differences for 
continuous outcomes if appropriate; 
however, none of the target outcomes 
were reported as continuous outcomes in 
the included studies. Meta-analyses were 
undertaken when data were sufficient to 
pool — namely, when two or more studies or 
comparisons reported the same outcome. A 
random-effects model was used.
The individual was used as the unit of 
analysis, when possible; however, if data on 
the number of individuals with primary and 
secondary outcomes of interest were not 
available, the information was extracted as 
it was presented — for example, the number 
of events (for example, UTI episodes) in each 
group. Investigators or study sponsors were 
contacted to provide missing data, where 
feasible. 
The I 2 statistic was used to measure 
heterogeneity among the included trials. The 
authors prespecified that a funnel plot would 
be created if >10 studies were included; 
however, <10 studies were included. If data 
allowed, the following subgroup analyses 
were prespecified: by comparison, and by 
duration of intervention. Data were sufficient 
to conduct a subgroup analysis by comparison 
(with antibiotic versus with control) only. 
It was planned that a sensitivity analysis 
would be conducted by including, versus 
excluding, studies with three or more 
domains rated at high risk of bias; however, 
as no studies were rated at high risk for three 
or more domains, that sensitivity analysis 
was not conducted. 
‘Summary of findings’ table
One author assessed the quality of evidence 
using the Grading of Recommendations, 
Assessment, Development and Evaluations 
approach,13 as recommended by the 
Cochrane collaboration.12 A summary of 
findings table was created using the following 
outcomes:
• patients remaining asymptomatic;
• patients remaining abacteriuric;
• number of symptomatic UTI episodes;
• number of bacteriuric UTI episodes; and
• adverse outcomes.
The two comparisons in the summary 
of findings table were for: methenamine 
hippurate versus any antibiotic and 
methenamine hippurate versus control 
(placebo or antiseptic iodine perineal wash). 




The searches across three databases yielded 
354 unique records. A backwards (cited) and 
forwards (citing) citation analysis yielded 
an additional 176 records, and the clinical 
registry search returned 11 records; after 
deduplication, this resulted in a total of 
458 records to screen. In total, 416 records 
were excluded after screening the title and 
abstract; 42 records were obtained for full-text 
screening, which included 41 references from 
the database searches and one clinical registry 
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Records identified through
database searching (n = 354)
Additional records identified
through other sources (n = 187)
Duplicates removed (n = 83)
Records screened
(n = 458)
Full-text articles assessed for
eligibility (n = 42)
Studies included in
qualitative synthesis and





reasons (n = 36)
(see Supplementary
Table S2)
Figure 1. PRISMA flow diagram.
Random sequence generation
(selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel
(performance bias)
Blinding of outcome assessment
(detection bias)
Incomplete outcome data (attrition bias)








Low risk of bias Unclear risk of bias High risk of bias
Figure 2. Risk of bias graph: review authors' 
judgements about each risk of bias item presented as 
percentages across all included studies.
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record that included results information. 
Supplementary Table S1 outlines eligible 
ongoing studies with no published or reported 
results. After full-text screening, 36 references 
were excluded; the characteristics of excluded 
studies are given in Supplementary Table S2. 
Six studies were included in the qualitative 
synthesis and meta-analysis (Figure 1).5,14–18
Risk of bias 
Due to the age of the included studies 
(five of the six included studies were 
>30 years old), the overall risk of bias was 
generally unclear. When these studies 
were published, reporting guidelines were 
not routinely used, which had an impact 
on the quality and degree of information 
reported: notably, sequence generation, 
allocation concealment, and blinding (both of 
participants and personnel, and of outcome 
assessment) were unclear (Figure 2). No 
evidence of incomplete outcome data or 
selective reporting of outcomes was found. 
The authors’ conflicts of interest and study 
Study/subgroup
Patients remaining asymptomatic after 6 or 12 months
Patients remaining abacteriuric after 12 months
Number of symptomatic UTI episodes after 6 or 12 months





Heterogeneity: τ2 = 0.69; χ2 = 4.59, df = 1 (    = 0.03);   2 = 78%
Test for overall effect: Z = 0.00 (    = 1.00)
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Heterogeneity: τ2 = 0.28; χ2 = 5.62, df = 1 (    = 0.02);   2 = 82%
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1.16 (0.68 to 1.96)
0.27 (0.15 to 0.47)
0.56 (0.13 to 2.35)




Heterogeneity: τ2 = 0.43; χ2 = 3.46, df = 1 (    = 0.06);    2 = 71%
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Heterogeneity: τ2 = 0.09; χ2 = 3.95, df = 2 (    = 0.14);   2 = 49%


























0.46 (0.28 to 0.76)
0.62 (0.28 to 1.38)
1.00 (0.56 to 1.78)
0.65 (0.40 to 1.07)
—
1.1.1 Methenamine hippurate versus any antibiotic
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Figure 3. Prevention of UTI meta-analysed outcomes. 
aRisk of bias: A = random sequence generation 
(selection bias); B = allocation concealment (selection 
bias); C = blinding of participants and personnel 
(performance bias); D = blinding of outcome 
assessment (detection bias); E = incomplete outcome 
data (attrition bias); F = selective reporting (reporting 
bias); and G = other bias. df = degrees of freedom. 
CI = confidence interval. IV = inverse variance. 
Log = natural logarithm. RR = rate ratio. SE = standard 
error. UTI = urinary tract infection.
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funding were also inadequately described in 
most trials.
Characteristics of included studies
Five of the included studies were published 
RCTs,5,14–17 and one was a clinical trial 
registry record with results provided.18 All 
were parallel RCTs, evenly split between two-
arm and three-arm trials. Two studies were 
published in Norwegian;16,17 the remaining 
four were published in English.5,14,15,18 
Characteristics of all six studies included in 
the review are given in Table 1. 
A total of 557 participants were included in 
the trials, of which 447 were analysed; only 
one study16 involved <50 participants. Three 
studies compared methenamine hippurate 
with a placebo or control, and three compared 
the efficacy of methenamine hippurate with 
antibiotics — namely, trimethoprim (two 
trials15,18) and nitrofurantoin (one trial14). One 
RCT15 examined a second non-antibiotic 
comparator, povidone-iodine solution, a 
common antiseptic perineal wash.
Prevention of UTI
Patients remaining asymptomatic after 
6 or 12 months. Methenamine hippurate 
versus antibiotics showed a non-statistically 
significant trend of benefit for methenamine 
hippurate (RR 0.65, 95% confidence interval 
[CI] = 0.40 to 1.07), and heterogeneity was 
moderate (49%). Methenamine hippurate 
versus control (placebo or antiseptic iodine 
perineal wash) showed a non-statistically 
significant difference between groups (RR 
1.0, 95% CI = 0.27 to 3.66), and heterogeneity 
was high (78%) (Figure 3).
Patients remaining abacteriuric after 
12 months. Methenamine hippurate versus 
any antibiotic showed a trend to benefit 
for methenamine hippurate, but a non-
statistically significant difference (RR 0.80, 
95% CI = 0.62 to 1.03), with low heterogeneity 
(23%) (Figure 3). 
Number of symptomatic UTI episodes after 
6 or 12 months. Methenamine hippurate 
versus any antibiotic showed a trend to 
benefit for methenamine hippurate, but no 
statistically significant difference (RR 1.95, 
95% CI = 0.87 to 4.38). Heterogeneity 
was high (82%). Methenamine hippurate 
versus control (placebo or antiseptic 
iodine perineal wash) showed a trend to 
benefit for methenamine hippurate, but no 
statistically significant difference between 
groups (RR 0.56, 95% CI = 0.13 to 2.35). 
Heterogeneity was high (93%) (Figure 3). 
Number of bacteriuric episodes after 
12 months. Methenamine hippurate versus 
any antibiotic showed a trend to benefit for 
methenamine hippurate, but no statistically 
significant difference between groups 
(RR 2.09, 95% = CI 0.72 to 6.09), with high 
heterogeneity (71%) (Figure 3). One study5 
reported on the number of patients with 
post-natal bacteriuria, finding no significant 
difference between methenamine hippurate, 
methenamine mandelate, and no-treatment 
groups (data not shown).
Adverse events
The most common adverse events reported 
in all studies5,14–18 were nausea, headache, 






Heterogeneity: τ2 = 0.00; χ2 = 0.06, df = 1 (    = 0.81);   2 = 0%
Test for overall effect: Z = 0.31 (    = 0.76)





















1.57 (0.17 to 14.93)
1.00 (0.06 to 17.62)




Heterogeneity: τ2 = 1.85; χ2 = 16.46, df = 4 (    = 0.002);  2 = 76%
Test for overall effect: Z = 0.17 (    = 0.87)

















hippurate, n Comparison, n Risk of biasa
















Heterogeneity: τ2 = 2.62; χ2 = 15.70, df = 2 (    = 0.0004);   2 = 87%


























0.13 (0.04 to 0.35)
2.64 (0.73 to 9.53)
1.50 (0.39 to 5.71)
0.77 (0.11 to 5.46)
—
2.3.1 Methenamine hippurate versus any antibiotic
? ? ? ?+ + +
+
? ?? ??+ –
? ? ?+ + +
? ? ? ?+ + +











Figure 4. Number of patients with adverse outcomes: 
methenamine hippurate versus comparator – sub-
grouped by comparator type (any antibiotic, control). 
aRisk of bias: A = random sequence generation 
(selection bias); B = allocation concealment (selection 
bias); C = blinding of participants and personnel 
(performance bias); D = blinding of outcome 
assessment (detection bias); E = incomplete outcome 
data (attrition bias); F = selective reporting (reporting 
bias); and G = other bias. CI = confidence interval. 
df = degrees of freedom.
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was no statistically significant difference in the 
number of patients experiencing any adverse 
events when methenamine hippurate was 
compared with any antibiotic (odds ratio [OR] 
0.77, 95% CI = 0.11 to 5.46), or with control 
(OR 1.32, 95% CI 0.23 to 7.77) (Figure 4). 
There was also no overall difference between 
methenamine hippurate and any comparator 
(total OR 0.89, 95% CI = 0.21 to 3.67). 
Antibiotic use 
The use of antibiotics outside of an 
intervention was indirectly reported in three 
trials;5,16,17 in each, antimicrobials were 
utilised to treat those participants who 
experienced a recurrent UTI during the trial 
(data not shown). 
Two studies16,17 reported that, in the 
case of symptoms of UTI and a positive 
bacteriological urine test, the intervention/
comparator was ceased; antibiotic therapy 
was initiated and used until sterile urine was 
achieved, whereby prophylactic treatment 
was resumed. One study16 reported seven 
symptomatic UTI recurrences in the 
methenamine hippurate group and 29 in the 
placebo group, each of which might have 
required the initiation of antibiotics. Similarly, 
another study17 reported 19 recurrences 
in the group receiving 2 g methenamine 
hippurate compared with four recurrences 
in the arm receiving a dose of 1 g and 26 
recurrences in the placebo group (data not 
shown).
One study5 specified that patients 
received antibiotics on developing clinical 
pyelonephritis: 20% of participants receiving 
methenamine hippurate, 13% of those 
receiving methenamine mandelate, and 
25% of those in the control group were 
diagnosed with pyelonephritis (data not 
shown). 
Antibiotic resistance 
Antibiotic resistance was poorly reported 
among the included studies as only three 
RCTs investigated sensitivity patterns 
of bacteria causing the infection.14,15,18 In 
one trial,14 authors reported that 38% of 
recurrent UTIs were caused by resistant 
strains; however, they did not report the 
between group difference. In another trial,15 
authors reported that 82% of the isolated 
strains were resistant to the intervention 
antibiotic arm (trimethoprim) compared 
with 3% in the methenamine hippurate 
arm. Authors in the third trial18 reported a 
higher number of resistant strains identified 
in the methenamine hippurate arm (n = 58) 
compared with the antibiotic arm (n = 30); 
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were provided to explain the difference (see 
Supplementary Table S3). 
Adherence
Although all studies reported that 
methenamine hippurate was used for 
a minimum duration of 6 months, which 
may raise concerns about adherence 
to the prophylaxis, some data suggests 
this may be acceptable to patients. For 
example, one study14 found a mean longer 
adherence to therapy for methenamine 
hippurate (196 days) than for nitrofurantoin 
(66 days), and another18 suggests a mean 
higher adherence in the group receiving 
methenamine hippurate than in the group 
receiving trimethoprim, when measured 
on the eight-item Morisky Medication 
Adherence Scale (data not shown). 
Summary of findings tables
Table 2 shows the summary of findings 
table for methenamine hippurate versus any 
antibiotic; Table 3 shows the summary of 




Six studies evaluating oral methenamine 
hippurate for preventing UTI in women 
with recurrent UTI were identified. Included 
studies showed a trend towards the benefit 
of methenamine hippurate for use to prevent 
recurrent UTI, although meta-analyses 
showed no statistically significant differences 
between methenamine hippurate and any 
comparators. 
Strengths and limitations 
This review provides rigour by excluding 
studies at high risk of bias due to confounding 
variables (such as post-surgery preventive 
studies and those involving women with 
indwelling catheters), thereby rendering 
the results more relevant to women in the 
community. 
There are limitations, however: only a 
small number of studies were included and 
there are several reasons why the findings of 
the individual studies should be interpreted 
with caution. Five of the studies5,14–17 were 
published >30 years ago and the most 
recent study18 was a clinical trial record, not 
a peer-reviewed publication. The included 
studies also featured: considerable clinical 
and statistical heterogeneity; poor reporting 
of bacterial resistance as one of the harms 
of using antibiotics in trials with an antibiotic 
arm; and general unclear risk of bias. In 
addition, only one study reported the use of 
methenamine mandelate and the sample 
size was small,5 hindering the reviewers 
from including methenamine mandelate in 
the analysis. This constitutes a deviation from 
the protocol, which specified that subgroup 
analyses and sensitivity analyses would be 
conducted; these could not be carried out 
because of the paucity of available data.
Comparison with existing literature
A Cochrane systematic review previously 
assessed methenamine hippurate for 
prevention of UTIs.7 It included studies with 
the following characteristics: RCTs and 
quasi-RCTs, looking at all population groups, 
and comparing intervention to control/no 
treatment only. The review showed some 
benefit for methenamine hippurate for 
preventing UTIs. The review presented here 
differs in that it only includes studies that 
were RCTs (the clinical trial record was 
an unpublished RCT study), comparing 
intervention to both control/no treatment 
and to any antibiotic (as this is one of the 
indications where antibiotics are routinely 
prescribed for a long duration). Moreover, it 
also focuses on women in the community, 
excluding studies with any male participants 
and those including participants at high 
risk of UTI infections (that is, those with 
abnormal renal tract anatomy, those who 
are immunocompromised, or those who 
have spinal cord injuries), which improves 
the applicability of the results to the majority 
of UTI cases seen in the community.
Similarly to the Cochrane review, the 
authors also found an overall low rate of 
adverse events, which suggests that 
methenamine hippurate is unlikely to be 
causing any harms; however, there is a 
need to explore this further in larger RCTs 
as methenamine hippurate, as a treatment, 
must be taken frequently over a long period 
of time (up to 12 months). 
The authors are aware of an ongoing study 
that investigates prophylaxis methenamine 
hippurate use against antibiotic;19 however, 
the data were not available. 
Implications for research and practice
Methodological and reporting limitations, 
as well as the small volume of available 
evidence, preclude a firm recommendation 
about the use of methenamine hippurate 
for prophylaxis in women with recurrent 
UTIs. The minimal reporting of harms 
from methenamine hippurate, along with 
the trend towards its benefit in reducing 
recurrent UTI, suggests a possible avenue 
to further investigate methenamine salts’ 
benefits for preventing recurrent UTIs.
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